Viatris Analyst Price Targets - Benzinga

Viatris Inc

VTRSNASDAQ

Trade with Public

Trade with Public

$16.34

-0.55-3.26%

가까이에: Aug 28, 5:00 PM EST

$16.30

-0.037-0.23%

시간외: Aug 28, 7:16 PM EST

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 옵션 주식 보고서

Viatris Analyst Price Targets

Wall Street analyst price targets and consensus rating for Viatris (VTRS).

Price Target Range — 9 Quarters

Analyst Consensus — 8 Analysts

4Buy

3Hold

1Sell

Consensus RatingBuy# Analysts8Avg. Consensus PT$14Upside to Avg. PT-12.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 19, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$17→$22
May 8, 2026	JP Morgan	Chris Schott	PT Raise	Neutral	$17→$18
May 8, 2026	Truist Securities	Srikripa Devarakonda	PT Raise	Buy	$18→$20
Mar 24, 2026	Barclays	Glen Santangelo	PT Raise	Overweight	$15→$17
Jan 28, 2026	Piper Sandler	David Amsellem	PT Raise	Neutral	$9→$12
Jan 16, 2026	Argus Research	—	Upgrade	Hold→Buy	$15
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$15
Oct 15, 2025	Truist Securities	Srikripa Devarakonda	Initiate	Buy	$15
Jun 6, 2025	Goldman Sachs	Matt Dellatorre	Initiate	Neutral	$10
Mar 7, 2025	Jefferies	Glen Santangelo	PT Cut	Buy	$15→$13
Mar 5, 2025	Piper Sandler	David Amsellem	PT Cut	Neutral	$14→$10
Feb 28, 2025	Barclays	Balaji Prasad	PT Cut	Underweight	$12→$9
Feb 28, 2025	B of A Securities	Jason Gerberry	PT Cut	Underperform	$11→$10
Dec 6, 2024	Piper Sandler	David Amsellem	PT Raise	Neutral	$13→$14
Nov 8, 2024	Barclays	Balaji Prasad	PT Raise	Underweight	$11→$12
Jul 19, 2024	Jefferies	Glen Santangelo	Reinstates	Buy	$15
Mar 28, 2024	Piper Sandler	David Amsellem	PT Raise	Neutral	$11→$13
Nov 22, 2023	Piper Sandler	David Amsellem	PT Raise	Neutral	$10→$11
Oct 23, 2023	B of A Securities	Jason Gerberry	Downgrade	Neutral→Underperform	$9

More with Benzinga EdgeGet Access

Analyst Ratings News

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ratings page provides latest analyst takes on top stocks, sorted by accuracy. Ratings for three high-yielding health care stocks: VTRS, MDT, GSK. VTRS to report Q2 results on Aug.6, MDT recalls certain catheter system, GSK reports positive trial results. Benzinga Pro's newsfeed provides real-time alerts.

Avi Kapoor

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst ratings for high-yielding stocks, including accuracy rates.

Avi Kapoor

PRO
JP Morgan Maintains Neutral on Viatris, Raises Price Target to $18

JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $17 to $18.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Viatris, Raises Price Target to $20

Truist Securities analyst Srikripa Devarakonda maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $18 to $20.

Benzinga Newsdesk

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga readers can check analyst takes on stocks at Analyst Stock Ratings page.

Avi Kapoor

PRO
Barclays Maintains Overweight on Viatris, Raises Price Target to $17

Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the price target from $15 to $17.

Benzinga Newsdesk